av大片在线观看,国产无套在线

熱門搜索化學品最多只顯示前20條，請點擊“搜索化學品”查看所有結果

CAS登錄號

中文名

英文名

分子結構式

分子式

詳情

供應商

169624-67-3

N-芴甲氧羰基-苯丙氨酰-甘氨酸

Fmoc-Phenylalanyl-glycine;
Fmoc-phe-gly-OH

Cyclo(glycyl-D-leucyl-L-phenylalanylglycyl-L-phenylalanyl-L-leucyl),trihydrate (9CI);
1,4,7,10,13,16-Hexaazacyclooctadecane,cyclic peptide deriv.;
Cyclo(L-Phe-L-Leu-Gly-D-Leu-L-phe-gly-) trihydrate

C34H46N6O6.3H2O

詳情

供應商

128050-88-4

Cyclo(glycyl-L-leucyl-L-phenylalanylglycyl-D-phenylalanyl-L-leucyl),trihydrate (9CI);
1,4,7,10,13,16-Hexaazacyclooctadecane,cyclic peptide deriv.;
Cyclo(L-Leu-L-phe-gly-D-Phe-L-Leu-Gly-) trihydrate

C34H46N6O6.3H2O

詳情

供應商

103340-16-5

Glycine,N-[N-[N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl]glycyl]- (9CI);
BOC-phe-gly-GLY-OH;
BOC-L-PHENYLGLYCYL GLYCINE

L-Phenylalaninamide,3,5-diiodo-L-tyrosyl-D-alanylglycyl-N-(2-hydroxyethyl)-Na-methyl- (9CI);
[3,5-DIL-TYR1,D-ALA2,N-ME-PHE4,GLY5-OL]-ENKEPHALIN;
3,5-DIIODO-TYR-D-ALA-GLY-N-ME-phe-glyCINOL;
3,5-DIIODO-TYR-D-ALA-GLY-N-METHYL-phe-gly-O;
[3,5-DIIODO-TYR1]-DAGO;
(3,5-DIIODO-TYR1)-DAGO ACETATE SALT;
(3,5-DIIODO-TYR1)-DAGO ACOH;
[3,5-DIIODO-TYR1, D-ALA2, N-ME-PHE4, GLYCINOL5]-ENKEPHALIN;
(3,5-DIIODO-TYR1,D-ALA2,N-ME-PHE4,GLYCINOL5)-ENKEPHALIN ACETATE SALT

L-Phenylalaninamide,glycyl-N-[2-[(aminocarbonyl)hydrazono]ethyl]- (9CI);
H-GLY-phe-gly-ALDEHYDE SEMICARBAZONE ACETATE SALT;
H-GLY-phe-gly-ALDEHYDE SEMICARBAZONE ACOH;
glycyl-phenylalanyl-glycine-semicarbazone;
H-Gly-phe-gly-aldehyde semicarbazone

Nociceptin (1-13)-NH2;
NOCICEPTIN (1-13) AMIDE;
NOCICEPTIN (1-13)NH2;
phe-gly-GLY-PHE-THR-GLY-ALA-ARG-LYS-NH2;
phe-gly-GLY-PHE-THR-GLY-ALA-ARG-LYS-SER-ALA-ARG-LYS-NH2;
ORPHANIN FQ (1-13) AMIDE;
H-phe-gly-GLY-PHE-THR-GLY-ALA-ARG-LYS-SER-ALA-ARG-LYS-NH2

Substance P,2-(3,4-didehydro-L-proline)-4-(3,4-didehydro-L-proline)- (9CI);
(3,4-DEHYDRO-PRO2,4)-SUBSTANCE P;
[DEHYDRO-PRO2,4]-SUBSTANCE P;
H-ARG-3,4-DEHYDRO-PRO-LYS-3,4-DEHYDRO-PRO-GLN-GLN-PHE-phe-gly-LEU-MET-NH2;
ARG-DELTA-PRO-LYS-DELTA-PRO-GLN-GLN-PHE-phe-gly-LEU-MET-NH2;
ARG-3,4-DEHYDRO-PRO-LYS-3,4-DEHYDRO-PRO-GLN-GLN-PHE-phe-gly-LEU-MET-NH2;
(DEHYDO-PRO2,4)-SUBSTANCE P;
Substance P, [dehydro-Pro2,4]

Substance P,1-de-L-arginine-2-de-L-proline-3-de-L-lysine-4-de-L-proline-5-(5-oxo-L-proline)-(9CI);
GLP-GLN-PHE-phe-gly-LEU-MET-NH2;
[GLP5] SUBSTANCE P (5-11);
PYR-GLN-PHE-phe-gly-LEU-MET-NH2;
(PYR5)-SUBSTANCE P (5-11);
SUBSTANCE P [PGLU5]-FRAGMENT 5-11;
PGLU-GLN-PHE-phe-gly-LEU-MET-NH2;
pglu5-substance P fragment 5-11;
Substance P, fragment 5-11, [pGl5]

Substance P,1-de-L-arginine-2-de-L-proline-3-de-L-lysine-4-D-alanine- (9CI);
D-ALA-GLN-GLN-PHE-phe-gly-LEU-MET-NH2;
(D-ALA4)-SUBSTANCE P (4-11);
H-D-ALA-GLN-GLN-PHE-phe-gly-LEU-MET-NH2;
SUBSTANCE P OCTAPEPTIDE D-ALA-4-FRAGMENT 4-11);
Substance P, fragment 4-11, (D-Ala4)

4-11-Substance P;
SubstanceP, 1-de-L-arginine-2-de-L-proline-3-de-L-lysine-;
37: PN: WO2007058336 SEQID:37 claimed protein;
H-Pro-Gln-Gln-Phe-phe-gly-Leu-Met-NH2;
Substance P(4-11)

ALA-ARG-LYS-ARG-GLU-ARG-THR-TYR-SER-phe-gly-HIS-HIS-ALA

AKTIDE-2T;
ALA-ARG-LYS-ARG-GLU-ARG-THR-TYR-SER-phe-gly-HIS-HIS-ALA;
AKTIDE-2T;
AKT/PKB/RAC-PROTEIN KINASE SUBSTRATE [ARKRERTYSFGHHA];
ARKRERTYSFGHHA;
H-ALA-ARG-LYS-ARG-GLU-ARG-THR-TYR-SER-phe-gly-HIS-HIS-ALA-OH;
AKT/PKB/Rac - Protein Kinase Substrate

ASP-ARG-LEU-TYR-SER-phe-gly-LEU-NH2

ALLATOSTATIN IV;
ALLATOSTATIN IV;
H-ASP-ARG-LEU-TYR-SER-phe-gly-LEU-NH2;
DRLYSFGL-NH2;
ASP-ARG-LEU-TYR-SER-phe-gly-LEU-NH2;
TYPE A ALLATOSTATIN IV;
Type A Allatostatin IV Asp-Arg-Leu-Tyr-Ser-phe-gly-Leu-NH2

SER-ASN-ASN-phe-gly-ALA-ILE-LEU-SER-SER

H-SER-ASN-ASN-phe-gly-ALA-ILE-LEU-SER-SER-OH;
H-SER-ASN-ASN-phe-gly-ALA-ILE-LEU-SER-SER-OH;
AMYLIN FRAGMENT 20-29 HUMAN;
AMYLIN (20-29);
AMYLIN (20-29) (HUMAN);
SNNFGAILSS;
SER-ASN-ASN-phe-gly-ALA-ILE-LEU-SER-SER;
diabetes associated peptide fragment 20-29 human

N-[3-(2-呋喃基)丙烯酰]-L-苯丙氨酰甘氨酰甘氨酸

FAPGG;
FA-phe-gly-GLY-OH;
FAPGG;
3-(2-FURYL)ACRYLOYL-phe-gly-GLY-OH;
3-(2-FURYLACRYLOYL)-L-phe-gly-GLY;
ANGIOTENSIN-CONVERTING ENZYME SUBSTRATE;
N-[3-(2-FURYLACRYLOYL)]-L-PHENYLALANINE-GLYCL-GLYCINE;
arginine-glycine-proline-phenylalanine-proline-isoleucine

ARG-ARG-SER-SER-CYS-phe-gly-GLY-ARG-ILE-ASP-ARG-ILE-GLY-ALA-GLN-SER-GLY-LEU-GLY-CYS-ASN-SER-PHE-ARG-

ARG-ARG-SER-SER-CYS-phe-gly-GLY-ARG-ILE-ASP-ARG-ILE-GLY-ALA-GLN-SER-GLY-LEU-GLY-CYS-ASN-SER-PHE-ARG-;
H-ARG-ARG-SER-SER-CYS-phe-gly-GLY-ARG-ILE-ASP-ARG-ILE-GLY-ALA-GLN-SER-GLY-LEU-GLY-CYS-ASN-SER-PHE-ARG-TYR-OH;
ATRIAL NATRIURETIC PEPTIDE RAT FRAGMENT 3-28;
ATRIAL NATRIURETIC FACTOR (3-28) (RAT);
ATRIAL NATRIURETIC PEPTIDE (3-28), RAT;
A-TYPE (ATRIAL) NATRIURETIC PEPTIDE (RAT, 3-28);
ARG-ARG-SER-SER-CYS-phe-gly-GLY-ARG-ILE-ASP-ARG-ILE-GLY-ALA-GLN-SER-GLY-LEU-GLY-CYS-ASN-SER-PHE-ARG-TYR;
ANP (RAT, 3-28);
ANP (3-28), RAT

NATRIURETIC PEPTIDE, C-TYPE;
CNP

C-TYPE NATRIURETIC PEPTIDE (32-53) (HUMAN, PORCINE, RAT);
NATRIURETIC PEPTIDE, C-TYPE, HUMAN AND PORCINE;
GLY-LEU-SER-LYS-GLY-CYS-phe-gly-LEU-LYS-LEU-ASP-ARG-ILE-GLY-SER-MET-SER-GLY-LEU-GLY-CYS;
GLSKGCFGLKLDRIGSMSGLGC;
GLSKGCFGLKLDRIGSMSGLGC (DISULFIDE BRIDGE: 6-22);
H-GLY-LEU-SER-LYS-GLY-CYS-phe-gly-LEU-LYS-LEU-ASP-ARG-ILE-GLY-SER-MET-SER-GLY-LEU-GLY-CYS-OH;
H-GLY-LEU-SER-LYS-GLY-CYS-phe-gly-LEU-LYS-LEU-ASP-ARG-ILE-GLY-SER-MET-SER-GLY-LEU-GLY-CYS-OH (DISULFIDE BRIDGE: 6-22);
CNP;
CNP-22, HUMAN

HEMOKININ 1 (HUMAN)

HEMOKININ 1 (HUMAN);
H-THR-GLY-LYS-ALA-SER-GLN-PHE-phe-gly-LEU-MET-NH2;
HHK-1;
HK-1 (HUMAN);
HEK-1 (HUMAN);
HEMOKININ 1 (HUMAN);
THR-GLY-LYS-ALA-SER-GLN-PHE-phe-gly-LEU-MET-NH2

H-phe-gly-GLY-PHE-OH

phe-gly-GLY-PHE;
phe-gly-GLY-PHE;
H-phe-gly-GLY-PHE-OH;
phenylalanine-glycine-glycine-phenylalanine

ARG-PRO-LYS-PRO-GLN-GLN-PHE-phe-gly-LEU-MET-OME: RPKPQQFFGLM-OME

SUBSTANCE P (7-11);
SUBSTANCE P (7-11);
SUBSTANCE P FRAGMENT 7-11;
PHE-phe-gly-LEU-MET-NH2;
PENTA-SUBSTANCE P;
FFGLM-NH2;
H-PHE-phe-gly-LEU-MET-NH2;
SUBSTANCE P FRAGMENT 7-11 ACETATE);
L-Phe-L-phe-gly-L-Leu-L-Met-NH2

C31H44N6O5S

詳情

供應商

化工產品